Caroline Jones

Exploring subjective and objective outcome measures for the detection of gynaecological cancer-related lymphoedema

Caroline Jones

Reduction in Discharge Delays for Patients Admitted for Allogeneic and Autologous Stem Cell Transplantation: A Quality Improvement Initiative

Jenna Schlefman, Shipra Maheshwari, Caroline Jones, Isabel Burgess et autres

Introduction The discharge process following stem cell transplant (SCT) is complex, often confounded by events occurring prior to and on day of discharge. Among patients undergoing allogeneic and autologous SCT at the University of Virginia from 01/2022 to 12/2022, only 5% were …

us (code pays fourni par la source)

Quality Improvement Initiative of Patients with Acute Myeloid Leukemia Receiving Non-Intensive Therapy in Academic-Community Medicine Partnerships in Rural Appalachia

Natalie Pham, Jeffrey Lantz, Caroline Jones, Debamita Kundu et autres

Introduction: Studies have previously reported improved outcomes for patients with acute myeloid leukemia (AML) in academic over nonacademic settings potentially due to the availability of multidisciplinary teams, clinical trials and increased resources (median overall survival12.6 months vs. 7 months, p<0.001; Giri et. …

us (code pays fourni par la source)

Improving discharge times for patients admitted for allogeneic stem cell transplantation.

Shipra Maheshwari, Jenna Schlefman, Caroline Jones, Isabel Burgess et autres

290 Background: Among patients admitted for allogeneic stem cell transplant (SCT) at University of Virginia (UVA) Health from 01/2022 through 12/2022, 0% were discharged by noon, even when discharge was anticipated. The discharge of SCT recipients is dynamic, impacted by events occurring …

us (code pays fourni par la source)

MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications

Valerie Tran, Kiarash Salafian, Kenan Michaels, Caroline Jones et autres

PURPOSE OF REVIEW: Measurable residual disease (MRD) is integral in the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This review discusses the current methods used to evaluate MRD as well as the interpretation, significance, and incorporation of MRD in current …

us (code pays fourni par la source)

Clinical outcomes of patients receiving venetoclax and hypomethylating agents for AML in academic and academic-community partnerships.

Natalie Pham, Jeffrey Lantz, Caroline Jones, Debamita Kundu et autres

e23235 Background: Prior studies have reported improved outcomes for acute myeloid leukemia (AML) in academic over nonacademic settings potentially due to the availability of multidisciplinary teams, clinical trials and increased resources (1,2). Our institution has partnered with community practices to further evaluate …

us (code pays fourni par la source)

491: SBRT Focal Boost for Localised Prostate Cancer: Primary Outcomes of the SPARC Prospective Trial

Binnaz Yasar, Yae‐Eun Suh, Ewan Chapman, Luke Nicholls et autres

Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial

Binnaz Yasar, Yae‐Eun Suh, Ewan Chapman, Luke Nicholls et autres

PURPOSE: Dose-escalated radiation therapy is associated with better biochemical control at the expense of toxicity. Stereotactic body radiation therapy (SBRT) with dose escalation to the dominant intraprostatic lesion (DIL) provides a logical approach to improve outcomes in high-risk disease while limiting toxicity. …

gb, au (code pays fourni par la source)

Blinatumomab in Practice

Jeffrey Lantz, Natalie Pham, Caroline Jones, Daniel Reed et autres

us (code pays fourni par la source)

Treatment Outcomes with Hypomethylating Agents and Venetoclax for AML in the Community Compared to an Academic Setting

Jeffrey Lantz, Natalie Pham, Caroline Jones, Debamita Kundu et autres

Background: The treatment of acute myeloid leukemia (AML) in older and/or unfit patients consists of a combination of a hypomethylating agent (HMA), such as decitabine and azacitidine, with venetoclax, which can be safely administered in the ambulatory setting. In this study, we …

us (code pays fourni par la source)

Reducing Length of Stay for Patients with Acute Myeloid Leukemia Receiving Inpatient High-Dose Cytarabine Consolidation Chemotherapy

David Riley, Caroline Jones, Amy Morris, Jeremy Sen et autres

Abstract Background For patients receiving high dose cytarabine (HiDAC) at the University of Virginia Health System between 10/2019 and 10/2020, median length of stay (LOS) from time of clinic appointment to hospital discharge exceeded the expected standard treatment time (119.4 hours vs …

us (code pays fourni par la source)

Reducing length of stay for patients with acute myeloid leukemia receiving inpatient high-dose cytarabine consolidation chemotherapy.

Caroline Jones, David Riley, Amy Morris, Jeremy Sen et autres

257 Background: For patients receiving high dose cytarabine (HiDAC) at University of Virginia (UVA) Health between 10/2019 and 10/2020, median length of stay (LOS) from time of clinic appointment to hospital discharge was 119.35 hours. Standard treatment time should be 112 hours …

us (code pays fourni par la source)